Acute angle closure glaucoma induced by selective serotonin reuptake inhibitor, and reversed by agomelatine
CUKUROVA MEDICAL JOURNAL, vol.44, no.4, pp.1520-1523, 2019 (ESCI, TRDizin)
- Publication Type: Article / Article
- Volume: 44 Issue: 4
- Publication Date: 2019
- Doi Number: 10.17826/cumj.572186
- Journal Name: CUKUROVA MEDICAL JOURNAL
- Journal Indexes: Emerging Sources Citation Index (ESCI), TR DİZİN (ULAKBİM)
- Page Numbers: pp.1520-1523
- Çukurova University Affiliated: Yes
Abstract
Agomelatine, a MT1 (Melatonin) and MT2 receptor agonist and 5-HT2C (5-Hidroksitriptamin) antagonist, is an antidepressant agent used in the treatment of major depressive disorders. Intraocular pressure lowering effect of melatonin and its analogues have been demonstrated in a few experimental studies. In the present case report, we have documented the reversal of angle closure glaucoma by oral agomelatine in a patient with major depressive disorder under selective serotonine reuptake inhibitor treatment. The patient, who had previously been diagnosed with glaucoma, was also receiving antiglaucomatous treatment.